Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-23T08:24:21.368Z Has data issue: false hasContentIssue false
  • English
  • Français

Dopamine versus norepinephrine in the treatment of shock

Published online by Cambridge University Press:  11 May 2015

Nathan Coxford ,
Eddy Lang  and
Shawn Dowling
Nathan Coxford*
Affiliation:
Division of Emergency Medicine, University of Calgary, Calgary, AB
Eddy Lang
Affiliation:
Division of Emergency Medicine, University of Calgary, Calgary, AB
Shawn Dowling
Affiliation:
Division of Emergency Medicine, University of Calgary, Calgary, AB
*
736 37 Street NW, Calgary, AB T2N 3B9; [email protected]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

dopaminenorepinephrinereview
Type
Knowledge to Practice • Des connaissances à la Pratique
Information
Canadian Journal of Emergency Medicine , Volume 13 , Issue 6 , November 2011 , pp. 395 - 397
Copyright
Copyright © Canadian Association of Emergency Physicians 2011

References

REFERENCES

1.Vincent, JL, Biston, P, Devriendt, J, et al. Dopamine versus norepinephrine: is one better? Minerva Anestesiol 2009;75: 333–7.Google ScholarPubMed
2.Dellinger, RP, Levy, MM, Carlet, JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296–327, doi:10.1097/01.CCM.0000298158.12101.41.CrossRefGoogle ScholarPubMed
3.Povoa, PR, Carneiro, AH, Ribeiro, OS, et al. Influence of vasopressor agent in septic shock mortality. Results from the Portugese Community-Acquired Sepsis Study (SACiUCI study). Crit Care Med 2009;37:736–40, doi:10.1097/CCM. 0b013e3181958b1c.CrossRefGoogle Scholar
4.Sakr, Y, Reinhart, K, Vincent, JL, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006;34:589–97, doi:10.1097/01.CCM.0000201 896.45809.E3.CrossRefGoogle ScholarPubMed
5.Mullner, M, Urbanek, B, Havel, C, et al. Vasopressors for shock. Cochrane Database Syst Rev 2004;(3):CD003709.CrossRefGoogle ScholarPubMed
6.Overgaard, CB, Davik, V. Inotropes and vasopressors. Review of physiology and clinical use in cardiovascular disease. Circulation 2008;118:1047–56, doi:10.1161/CIRCULATIO-NAHA.107.728840.CrossRefGoogle ScholarPubMed
7.Patel, GP, Grahe, JS, Sperry, M, et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010;33:375–80, doi:10.1097/SHK. 0b013e3181c6ba6f.CrossRefGoogle ScholarPubMed
8.De Backer, D, Biston, P, Devriendt, J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779–89, doi:10.1056/NEJMoa0907118.CrossRefGoogle ScholarPubMed
9.Rivers, E, Nguyen, B, Havstad, S. Early goal-directed therapy in the treatment of severe sepsis and septic shock. NEnglJ Med 2001;345:1368–77, doi:10.1056/NEJMoa010307.CrossRefGoogle ScholarPubMed
10.Levy, JH. Treating shock-old drugs, new ideas. N Engl J Med 2010;362:841–3, doi:10.1056/NElMe1000091.CrossRefGoogle ScholarPubMed